Anaemia and heart failure: aetiology and treatment
Department of Cardiology, Jesselson Heart Center, Shaare Zedek Medical Center, Jerusalem, Israel
Correspondence and offprint requests to: Dan Tzivoni, MD, Professor of Medicine/Cardiology, Director, Department of Cardiology, Shaare Zedek Medical Center, 12 Hans Beyth Street, POB 3235, Jerusalem 91031, Israel. Email: cardio{at}szmc.org.il
Heart failure (HF) is a common disease associated with poor prognosis. Anaemia is commonly associated with HF due to bone marrow depression, reduced availability of iron and haemodilution, and is sometimes aggravated by too frequent blood testing. Low haemoglobin is very detrimental to the haemodynamic state of the patient with decreased cardiac output as it further diminishes the oxygen supply to the tissues. When anaemia is associated with HF. and renal failure, the patient enters a vicious cycle called cardio renal anaemia syndrome. The prognosis of patients with HF is worse as the haemoglobin is lower and even mild anaemia is associated with <1 year survival. Aggressive correction of the anaemia by subcutaneous injections of erythropoeitin and intravenous iron has been shown to improve the functional capacity and quality of life of patients with cardio renal anaemia syndrome and to reduce the need for hospitalization. However, intravenous iron can be detrimental because of increased formation of free radicals, oxidative stress and risk of infection. The level of haemoglobin needed to be achieved is not clear, but it seems indicated to maintain it above 12 g%.
Keywords: anaemia; heart failure; prognosis; renal failure; treatment